Table 4

Correlation summary of radiometric HPLC and HPLC MS peaks characterized in human excreta

Peak Designation	Name (PHA-Number)	¹⁴C-HPLC Retention Time	MH⁺	¹⁹F NMR Shift^4-a	Approximate Mean Abundance
		min	Da	ppm	%
M2	173558	7.2	326	−133.26	3.3
M4	142586	9.4	370	−122.07	45
M6	142300	10.9	370	−132.15	11
M10	142618 ^4-b	17.3	312	N.D.	1.0
M11	143010	17.7	356	N.D.	<0.5
M12	105368	NR (18.5)	296	−121.30	nq
M13	143131	20.1	356	−132.15	0.6
M14	143011	20.1	354	−121.48	<0.5
M15	144089	20.9	352	N.D.	<0.5
M17	141960 (impurity)	22.4	320	No fluorine	<0.5
M18	142620 ^4-b	24.2	352	N.D.	<0.5
M19a	100440	NR (25.2)	297	−121.47	nq
P	linezolid	25.4	338	−121.47	30

Only five compounds (bold font) represented >1.0% of dose. Not all trace compounds characterized are included in this summary.

N.D., not detected; NR, not radioactive; nq, not quantified.
↵4-a The ¹⁹F NMR shift (ppm) is given for compounds detected in the urine.
↵4-b Acid-catalyzed decomposition products of PNU-142586; not detected in the neutral NMR samples.